Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Estrogen Receptor-Positive Breast Cancer|Breast Cancer, Estrogen Receptor-Positive|ER+ Breast Cancer
Interventions: DRUG: entinostat|DRUG: exemestane|DRUG: Placebo
Sponsor: Syndax Pharmaceuticals